TickerTalks
Browse all tickers →
TickerTalks›$NTLA
NTNTLA

Intellia Therapeutics, Inc.

$NTLA·$1.3B·Biotechnology·Healthcare
$12.72-1.2%YTD+22.6%1Y+10.9%
Mentions · last 7 days
2026-08-21: 13 posts2026-08-22: 7 posts2026-08-23: 12 posts99-6%
Price updated 10m ago·X counts updated 8d ago
NTNTLA
$NTLAIntellia Therapeutics, Inc.
$12.72-1.20%99 posts-6%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NTLA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-08-31

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Intellia's ATTR-CM combo pitch: Vutrisiran + NTLA-2001 requires ~80% TTR knockdown for stasis, and IONS misses at 69.7% — 33% short interest sets a squeeze.

Intellia Therapeutics is a clinical-stage gene-editing biotech developing CRISPR/Cas9-based in-vivo therapies for ATTR (transthyretin amyloidosis), HAE (hereditary angioedema), and other genetic conditions. The equity is up 23% YTD and coiled around $13 as the ATTR-CM combo-therapy debate intensifies and short interest builds.

  • The revenue picture is small and lumpy: Q1 revenue was $15M and declined 9.5% YoY (Regeneron-milestone timing), consensus models $58M FY26 rising to $716M FY28 as NTLA-2001 potentially reaches commercialization — the equity trades on regulatory outcomes, not near-term revenue.
  • The ATTR-CM combo debate is the specific catalyst: bulls argue Vutrisiran already shows real combo benefit with the CRISPR knockdown mechanism, and that stasis (disease stabilization) requires roughly 80% TTR knockdown — a bar that competing IONS data misses at 69.7% — that's a genuinely differentiated positioning if it holds up.
  • The short-interest setup is combustible: roughly 33% short interest with a five-day short-coverage setup means any positive readout — a specific Phase 3 update, a partnership announcement, or FDA-alignment news — triggers a covering catalyst on top of the fundamental repricing.
  • Insider tape shows small selling: director John Leonard sold $287K in two Aug tranches at $12.60-$13 — modest at a $1.34B cap, but a real signal that management doesn't see current levels as materially undervalued; the CRISPR broader-cure framing from Doudna keeps the ecosystem narrative intact.

The path if the setup resolves higher is a Nov 5 Q3 print with specific NTLA-2001 combo or Phase 3 update plus continued CRISPR-broader-cure narrative — the tape breaks the coil upward as shorts get squeezed and the ATTR-CM combo thesis validates. What extends the drift is a Q3 with no specific catalyst plus continued FY26 revenue below consensus; that's when a stock at 25% of its 52-week range makes fresh lows as the science bets get repriced downward.

Agrees with X sentimentThe bullish X take — Intellia inside the ATTR-CM combo debate, Vutrisiran already showing real combo benefit versus BBIO-favored skeptics, pointing out stasis requires roughly 80% TTR knockdown which competing IONS data misses at 69.7%, CRISPR broader-cure framing from Doudna cited, and 33% short-interest with five-day-coverage setup framing as asymmetric — captures the specific technical-plus-scientific setup exactly.

What to watch: The Nov 5 Q3 print — specific NTLA-2001 combo or Phase 3 update plus continued CRISPR-broader-cure narrative breaks the coil upward on short-squeeze mechanics; no specific catalyst plus FY26 revenue below consensus is what makes fresh lows.

On the calendar: 2026-11-05 — Q3 2026 earnings

float missing

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment8 posts analyzed · as of 2026-08-30

Biotech posters lean firmly constructive on Intellia inside the ATTR-CM combo debate, arguing Vutrisiran already shows real combo benefit versus BBIO-favored skeptics and pointing out that stasis requires roughly 80% TTR knockdown, which competing IONS data misses at 69.7%. CRISPR broader-cure framing from Doudna is cited alongside a 33% short-interest, five-day-coverage setup that posters frame as asymmetric on any positive readout.

Read the AI verdict + X sentiment for $NTLA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops in vivo CRISPR-Cas9 gene editing therapies for ATTR amyloidosis and other systemic genetic diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NTLA.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $NTLA

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-60.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-6.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-23.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
23.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-57.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-31.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.80$-0.80-0.1%
Q1 2026May 11, 2026$-0.81$-0.92+12.0%
Q4 2025Feb 26, 2026$-0.83$-0.99+16.2%
Q3 2025Nov 6, 2025$-0.92$-1.02+9.8%
Next earningsThu, Nov 5·consensus EPS $-0.82

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$15.0M-9.5%85.4%-668%$-0.81$-117.4M
Q4 FY25$23.0M+78.8%73.9%-429%$-0.83$-69.4M
Q3 FY25$13.8M+51.3%-473%-809%$-0.92$-76.9M
Q2 FY25$14.2M+104.8%100%-772%$-0.98$-99.9M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$58.2M$14.1M – $93.7M-$3.20-$3.57 – -$2.7714
FY27$271.9M$2.0M – $1.6B-$1.82-$8.31 – $34.5914
FY28$716.5M$17.9M – $5.8B-$0.54-$10.04 – $43.6211
FY29$1.9B$71.6M – $14.6B$4.47-$1.12 – $44.095
FY30$3.0B$113.0M – $23.1B$9.84-$2.46 – $97.035

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.25%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-1.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+5.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β1.795-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 21John M LeonardCEO2.8K sh$36KSellAug 20John M LeonardCEO19.9K sh$251KSellJul 22Edward J DulacCFO8.1K sh$91KSellJul 2Edward J DulacCFO4.7K sh$84KSellJul 1Michael P DubeVP, Chief Accounting Officer2.6K sh$44K
+ 7 other (7 awards) in window

See when $NTLA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJun 158-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Intellia Therapeutics, Inc. (NTLA) made a Reg FD disclosure (Item 7.01) and reported other events (Item 8.01) in an 8-K filed June 15, 2026. Body unavailable — excerpt cuts off before the substance of the Reg FD disclosure is revealed.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

Intellia Therapeutics held its 2026 Annual Meeting on June 9, 2026, with three proposals voted on by shareholders. Class I directors Muna Bhanji and Brian Goff were elected (Jesse Goodman passed with a thinner margin — 43M for vs. 15.7M against), Deloitte & Touche LLP was ratified as independent auditor for fiscal year ending December 31, 2026, and named executive officer compensation was approved on a non-binding advisory basis (44.8M for, 13.8M against). Goodman's higher withhold vote (~27% against) is a notable governance signal worth monitoring. Routine annual meeting with no material financial or strategic implications.

8-KMaterial agreementApr 308-K — Item 1.01: Material agreement · Item 2.02: Earnings release
AI summary

NTLA reported period ending 2026-04-30 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

424B5Prospectus supplement (offering)Apr 29424B5
AI summary

NTLA filed a 424B5 prospectus supplement dated 2026-04-29, representing an active capital markets transaction. Priced at $15.87 per share. This represents immediate dilution to existing shareholders.

424B5Prospectus supplement (offering)Apr 27424B5
AI summary

NTLA filed a 424B5 prospectus supplement dated 2026-04-27, representing an active capital markets transaction. Priced at $15.87 per share. This represents immediate dilution to existing shareholders.

8-KPress release / Reg FDApr 278-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

NTLA filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-27. Covers: presented topline data from the HAELO Phase 3 trial of lonvoguran ziclumeran (“lonvo-z”) for the tre. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KCharter amendmentApr 108-K — Item 5.03: Charter amendment
AI summary

NTLA filed an 8-K (Item 5.03) dated 2026-04-10. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On April 7, 2026, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc.

+ 11 other (4 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gainszacks.com·7d agoIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·24d agoNTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenueszacks.com·24d agoIntellia Therapeutics Q2 Earnings Call Highlightsmarketbeat.com·25d agoIntellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcriptseekingalpha.com·25d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport